ClinicalTrials.gg
CompletedNCT02068027Updated Sep 26, 2017Results posted

Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy

A Phase 2 interventional study of Clonidine Gel 0.1% and Placebo in Painful Diabetic Neuropathy, Diabetic Neuropathy and Neuropathy, sponsored by BioDelivery Sciences International. Completed at 23 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-09-26.

Sponsored by BioDelivery Sciences International · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Diabetic Neuropathies with a site in United States — 12 open to participants now, 17 under way, none of them phase 3. Diabetic Neuropathies · United States.

Enrollment
31st of 145
260 · median 91
Started
2014
with 5 others
Phase 2
47 of 158
1 open now
Registered
95th of 158
by date
Lead sponsor
3 of 158
BioDelivery Sciences International

Among the 158 studies in Diabetic Neuropathies with a site in United States, this one is the 31st largest by enrollment of the 145 interventional ones that give a count, is one of 6 that started in 2014, is one of 47 in phase 2, and was the 95th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

12 of the 158 studies in Diabetic Neuropathies with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Diabetic Neuropathies with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether clonidine gel is an effective treatment for reducing the pain associated with painful diabetic neuropathy.

Read the detailed description

Study CLO 290 was a multicenter, randomized, double blind, placebo controlled, 2 arm parallel group study of Clonidine Gel in the treatment of pain associated with PDN. Subjects were randomly assigned in a 1:1 ratio to receive 1 of 2 treatments applied topically TID to both feet for 85 days: Clonidine Gel (3.9 mg of clonidine HCl total daily dose), or Placebo Gel (vehicle without clonidine). Approximately 140 adult subjects with symmetrical distal PDN were expected to be randomized into the study. However, a pre-planned fully blinded interim analysis was performed when 70 subjects had completed the study for the purpose of re estimating sample size. Following the recommendation of the independent, third party statistician who conducted the interim analysis, the sample size was adjusted to allow approximately 260 subjects to be randomized into the study.

The study included 5 phases: Screening Phase (up to 21 days duration), Baseline Phase (Day 14 to Day 8), Placebo Lead in Phase (Day -7 to Day 1), Double blind Treatment Phase (85 days), and a Post-treatment Follow up Phase (7 days, only for subjects not enrolling in the open label long term safety study, CLO 311).

03

Conditions studied

  • Painful Diabetic Neuropathy
  • Diabetic Neuropathy
  • Neuropathy

Keywords

  • Diabetes Mellitus
  • Pain
  • Foot pain
  • Neuropathy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has provided written .
  • The subject is an outpatient aged 18 to 85 years (inclusive) at the time of the Screening Visit.
  • The subject has Type 1 or Type 2 diabetes mellitus with glycemic control that has been optimized and has been stable on diet therapy, oral anti-hyperglycemic agents and/or insulin, for at least three (3) months prior to the Screening Visit.
  • The subject must be a male or non-pregnant, non-lactating female. Females must be practicing an acceptable method of , or be surgically sterile or (amenorrhea for ≥12 months). Non-pregnancy will be confirmed (as applicable) by a pregnancy test conducted at the Screening and Randomization Visits. Double-barrier methods, hormonal contraceptives, and abstinence are acceptable birth control methods for this study.
  • The subject has chronic pain attributable to a symmetrical stocking distribution neuropathy in the lower extremities for at least three (3) months. A loss of distal sensation and/or tingling paresthesia primarily in the toes and fingers is acceptable, but must be of secondary importance to the distal neuropathic pain. Pain should be clearly localized to the area of neuropathy (feet) and subjects should be able to distinguish this pain (the target pain) from other painful areas and conditions.
  • The subject has an average pain score relevant to the target pain in the feet of ≥4 on an 11-point Numeric Pain Rating Scale over the previous 24 hours at Screening.
  • The subject has a pain score of at least 2, on the 11-point Numeric Pain Rating Scale , within 30 minutes following topical 0.1% capsaicin application with occlusive dressing to the pretibial area.
  • The subject has a mean daily average pain score relevant to the target pain in the feet of ≥4 on an 11-point Numeric Pain Rating Scale during the Baseline Phase.
  • The subject has met the pain evaluation and scoring criteria at the end of the Placebo Lead-in Phase by having a mean daily average pain score relevant to the target pain in the feet of ≥4 on an 11-point Numeric Pain Rating Scale without having a decrease in their pain score greater than 20% compared to the Baseline Phase score in the 11-point Numeric Pain Rating Scale .
  • The subject has been medically stable for at least 30 days prior to the Screening Visit, and in the opinion of the Investigator, is in otherwise good general health based on medical history, physical examination, , and laboratory evaluation.
  • If taking chronic oral pain medications, the subject must be on a stable regimen for at least 14 days prior to the Baseline Visit with the expectation that the medications, dose(s) and schedule will remain stable throughout the study. For medications containing non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin, subjects must be on a stable dose for at least 7 days prior to the Baseline Visit. As needed pain medications will be limited to acetaminophen from Day -8 until the end of the treatment period. Low dose aspirin (81 mg/day) is not considered as analgesic therapy.
  • Subject is compliant with daily pain assessments during the Baseline Phase and Placebo Lead in Phase of the study by recording their Numeric Pain Rating Scale score at least 5 days and the last 3 days of the previous 7 days.
  • Subject is alert and has the capabilities of applying topical gel to both feet three times daily. A caregiver, trained by the study staff to apply study drug, would be a suitable alternative to self-application of the treatment.

Exclusion criteria

Exclusion Criteria:

  • The subject has neuropathy secondary to non-diabetic causes in the opinion of the Investigator (e.g., significant vasculitis, collagen vascular disorder, familial neuropathy, alcoholism, pernicious anemia, hepatitis, , syphilis, post-herpetic neuralgia, chronic inflammatory demyelinating polyradiculopathy, [HIV], medication-induced neuropathy, vitamin B12 deficiency).
  • The subject has a significant neurological disorder or a condition that can cause symptoms that mimic peripheral neuropathy or might confound assessment of painful diabetic neuropathy (e.g., stroke with distal neurological deficit, mononeuritis multiplex, lumbar radiculopathy, multiple sclerosis) or has significant asymmetric neuropathic signs and symptoms.
  • The subject has other sustained pain with intensity at or greater than the bilateral neuropathic pain in the feet/toes.
  • The subject is using an implanted medical device (e.g., spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for the treatment of pain.
  • The subject has no pin-prick sensitivity to Neuropen testing of non-calloused areas of the foot.
  • The subject is clinically hypotensive with a resting diastolic blood pressure \<60 mm Hg or a systolic blood pressure \<90 mm Hg.
  • The subject has recent history (within the past 3 months) or current symptoms of orthostatic hypotension with a sudden fall in blood pressure on standing accompanied by dizziness and lightheadedness.
  • The subject has a history of foot or toe amputation, or an active foot or toe ulcer.
  • The subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study.
  • The subject has a history of substance abuse disorder as defined by the , 4th Edition, Text Revision (DSM-IV-TR) within the past year, has current evidence for substance abuse disorder, is receiving medicinal treatment for drug abuse, or tests positive upon urine drug screen for a non-prescribed substance of abuse.
  • The subject has used capsaicin on the feet for greater than 2 consecutive weeks in the previous 3 months.
  • The subject has symptomatic or severe coronary insufficiency, cardiac conduction disturbances, myocardial infarction (within last 12 months), moderate to severe cerebrovascular disease, or severe (COPD) requiring oxygen therapy.
  • The subject has a serum creatinine value >2.0 mg/dL or a value for (ALT) or aspartate transaminase (AST) >2.5 times the at Screening.
  • The subject was dosed with an drug within 30 days prior to the Screening Visit.
  • The subject is likely to be noncompliant or unreliable in providing pain ratings as judged by the Investigator.
  • The subject has evidence of clinically significant peripheral vascular disease as evidenced by history of intermittent claudication or evidence of vascular ulcers, including venous stasis ulcers.
  • The subject has had prior treatment with clonidine topical gel.
  • The subject is currently taking or has taken clonidine in any form (oral, transdermal patch) over the past 4 weeks.
  • The subject has known or intolerance to clonidine.
  • Except for acetaminophen, the subject is currently receiving any medications that could affect neuropathic pain and is not at a stable dose for at least 14 days prior to the Baseline Visit (other than medications containing NSAIDs and aspirin which must be stable for 7 days prior to the Baseline Visit).
  • The subject is receiving non-oral pain medication(s) (transdermal, topical, subcutaneous, intramuscular, intravenous, intrarectal, sublingual, transmucosal) and/or using "alternative medicine" products or techniques (acupuncture, naturopathy, homeopathy, etc.) for pain treatment ≤7 days prior to the Baseline Visit.
  • Subject has a history of malignancy within the past 5 years with the exception of successfully treated non- basal cell or squamous cell carcinomas of the skin and/or localized carcinoma in situ of the cervix.
  • The subject has been hospitalized within 30 days of the Screening Visit, or is planning to have surgery during the study period.
  • The subject has clinical evidence of pedal edema or venous stasis disease associated with significant skin changes on physical examination.
  • The subject has a clinically relevant painful foot condition, such as tarsal tunnel syndrome, plantar fasciitis, Morton's neuroma, painful bunion, or arthritis of the foot/ankle, or has a condition that may be associated with numbness in the foot.
  • The subject has any dermatologic condition of the lower extremities that could affect study drug absorption (e.g., severe edema).
  • The subject has current symptoms of depression with a Beck Depression Inventory -II score >19 at Screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Clonidine Gel 0.1%

    Clonidine hydrochloride topical gel, 0.1%

    Drug: Clonidine Gel 0.1%

  • Placebo comparator
    Placebo

    Placebo gel of identical appearance as active treatment

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score

    The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 \[±3 days\]) in the Numeric Pain Rating Scale score assessing the "average pain in the past 24 hours in the painful areas of the feet" averaged over Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the primary efficacy endpoint, the mean change in pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model.

    Time frame: The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days])

Secondary outcomes

  1. Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores

    The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (worst score from Day -14 to Day -8) to End-of-Treatment (worst score during Days 78 to 84 \[±3 days\]) in the Numeric Pain Rating Scale score assessing the "worst pain in the past 24 hours in the painful areas of the feet" from Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the endpoint, the change in worst pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline worst pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model.

    Time frame: The change from Baseline (worse over Day -14 to Day -8) to End-of-Treatment (worse over Days 78 to 84 [±3 days])

07

Results

Posted Aug 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneClonidine Gel 0.1%Placebo
Started130130
Completed117114
Not completed1316

Outcome measures

PrimaryChange From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score

The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 \[±3 days\]) in the Numeric Pain Rating Scale score assessing the "average pain in the past 24 hours in the painful areas of the feet" averaged over Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the primary efficacy endpoint, the mean change in pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model.

Time frame:
The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days])
Reported as:
Mean · units on a scale
Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score
units on a scaleClonidine Gel 0.1%Placebo
Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score-1.6 ± 0.17-1.6 ± 0.19
Statistical analysis
  • Clonidine Gel 0.1% vs Placebo · Mixed Models Analysis · p = 0.4503 (MMRM imputing for missing data)
SecondaryMean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores

The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (worst score from Day -14 to Day -8) to End-of-Treatment (worst score during Days 78 to 84 \[±3 days\]) in the Numeric Pain Rating Scale score assessing the "worst pain in the past 24 hours in the painful areas of the feet" from Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the endpoint, the change in worst pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline worst pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model.

Time frame:
The change from Baseline (worse over Day -14 to Day -8) to End-of-Treatment (worse over Days 78 to 84 [±3 days])
Reported as:
Mean · units on a scale
Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores
units on a scaleClonidine Gel 0.1%Placebo
Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores-1.4 ± 0.11-1.4 ± 0.11
Statistical analysis
  • Clonidine Gel 0.1% vs Placebo · Mixed Models Analysis · p = 0.7350 (MMRM imputing for missing data)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clonidine Gel 0.1%0/130 (0%)12/130 (9.2%)38/130 (29.2%)
Placebo0/130 (0%)7/130 (5.4%)58/130 (44.6%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventClonidine Gel 0.1%Placebo
Acute myocardial infarctionCardiac disorders1/1301/130
ArrhythmiaCardiac disorders0/1301/130
Atrial fibrillationCardiac disorders1/1300/130
BradycardiaCardiac disorders1/1300/130
Ischaemic cardiomyophathyCardiac disorders1/1300/130
ColitisGastrointestinal disorders0/1301/130
Duodenal ulcerGastrointestinal disorders1/1300/130
OesophagititsGastrointestinal disorders0/1301/130
Back painMusculoskeletal and connective tissue disorders1/1300/130
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders1/1300/130
Most frequent other events
Most frequent other events
EventClonidine Gel 0.1%Placebo
HeachacheNervous system disorders10/13020/130
Back painMusculoskeletal and connective tissue disorders7/13011/130
Pain in extrimityMusculoskeletal and connective tissue disorders2/1308/130
Dry SkinSkin and subcutaneous tissue disorders3/1308/130
Upper respiratory tract infectionInfections and infestations5/1307/130
HyperkeratosisSkin and subcutaneous tissue disorders7/1301/130
Oedema peripheralGeneral disorders7/1303/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)Clonidine Gel 0.1%PlaceboTotal
Mean60.58 ± 10.45859.64 ± 11.22660.11 ± 10.838
Sex: Female, Male
Sex: Female, Male(Participants)Clonidine Gel 0.1%PlaceboTotal
Female5058108
Male8072152
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Clonidine Gel 0.1%PlaceboTotal
Hispanic or Latino183250
Not Hispanic or Latino11298210
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Clonidine Gel 0.1%PlaceboTotal
American Indian or Alaska Native213
Asian314
Native Hawaiian or Other Pacific Islander000
Black or African American303161
White9597192
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Clonidine Gel 0.1%PlaceboTotal
United States130130260
08

Study locations

23 sites
  • Phoenix, Arizona 85023, United States
  • Santa Monica, California 90404, United States
  • Walnut Creek, California 94598, United States
  • Milford, Connecticut 06460, United States
  • Waterbury, Connecticut 06708, United States
  • Bradenton, Florida 34205, United States
  • Brandon, Florida 33511, United States
  • Jupiter, Florida 33458, United States
  • Miami, Florida 33143, United States
  • Tampa, Florida 33606, United States
  • West Palm Beach, Florida 33401, United States
  • Columbus, Georgia 31904, United States
  • Evansville, Indiana 47714, United States
  • Kansas City, Kansas 66160, United States
  • Hazelwood, Missouri 63042, United States
  • Winston-Salem, North Carolina 27103, United States
  • Warwick, Rhode Island 02886, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Dallas, Texas 75230, United States
  • Houston, Texas 77055, United States
  • San Antonio, Texas 78229, United States
  • Virginia Beach, Virginia 23451, United States
  • Renton, Washington 98057, United States
09

References and documents

Publications

  • Serednicki WT, Wrzosek A, Woron J, Garlicki J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J, Zajaczkowska R. Topical clonidine for neuropathic pain in adults. Cochrane Database Syst Rev. 2022 May 19;5(5):CD010967. doi: 10.1002/14651858.CD010967.pub3. PubMed 35587172 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2014
First posted
Feb 20, 2014
Start
Mar 2014
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Aug 24, 2017
Last update
Sep 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02068027
Lead sponsor
BioDelivery Sciences International
Responsible party
Sponsor
First posted
Feb 20, 2014
Start date
Mar 2014
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Aug 24, 2017
Last update
Sep 26, 2017

Study contacts

Aziz Shaibani, MD
principal investigator · Nerve & Muscle Center of Texas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clonidine

Start the discussion